269 related articles for article (PubMed ID: 14722462)
1. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
[TBL] [Abstract][Full Text] [Related]
3. Change in intraocular pressure during long-term use of loteprednol etabonate.
Novack GD; Howes J; Crockett RS; Sherwood MB
J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
[TBL] [Abstract][Full Text] [Related]
4. Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report.
Lu E; Fujimoto LT; Vejabul PA; Jew RL
Optometry; 2011 Jul; 82(7):413-20. PubMed ID: 21543264
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
Rajpal RK; Roel L; Siou-Mermet R; Erb T
J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
[TBL] [Abstract][Full Text] [Related]
6. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
Dell SJ; Shulman DG; Lowry GM; Howes J
Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
[TBL] [Abstract][Full Text] [Related]
7. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
[TBL] [Abstract][Full Text] [Related]
9. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.
Dell SJ; Lowry GM; Northcutt JA; Howes J; Novack GD; Hart K
J Allergy Clin Immunol; 1998 Aug; 102(2):251-5. PubMed ID: 9723669
[TBL] [Abstract][Full Text] [Related]
11. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
Friedlaender MH; Howes J
Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
[TBL] [Abstract][Full Text] [Related]
12. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
Holland EJ; Djalilian AR; Sanderson JP
Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
Berdy GJ; Stoppel JO; Epstein AB
Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
[TBL] [Abstract][Full Text] [Related]
14. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
[TBL] [Abstract][Full Text] [Related]
15. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
Abelson M; Howes J; George M
J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
[TBL] [Abstract][Full Text] [Related]
16. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
Lane SS; Holland EJ
J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ocular inflammatory conditions with loteprednol etabonate.
Pavesio CE; Decory HH
Br J Ophthalmol; 2008 Apr; 92(4):455-9. PubMed ID: 18245274
[TBL] [Abstract][Full Text] [Related]
19. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
Asbell P; Howes J
CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
[TBL] [Abstract][Full Text] [Related]
20. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
Gong L; Sun X; Qu J; Wang L; Zhang M; Zhang H; Wang L; Gu Y; Elion-Mboussa A; Roy L; Zhu B
Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
